208 related articles for article (PubMed ID: 19414350)
1. Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells.
Tanaka T; Kawashima H; Ohnishi K; Matsumura K; Yoshimura R; Matsuyama M; Kuratsukuri K; Nakatani T
Anticancer Res; 2009 Apr; 29(4):1089-94. PubMed ID: 19414350
[TBL] [Abstract][Full Text] [Related]
2. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.
Goffinet M; Thoulouzan M; Pradines A; Lajoie-Mazenc I; Weinbaum C; Faye JC; Séronie-Vivien S
BMC Cancer; 2006 Mar; 6():60. PubMed ID: 16539721
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
Quinn JE; Brown LG; Zhang J; Keller ET; Vessella RL; Corey E
Prostate Cancer Prostatic Dis; 2005; 8(3):253-9. PubMed ID: 15999121
[TBL] [Abstract][Full Text] [Related]
5. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
Kellinsalmi M; Mönkkönen H; Mönkkönen J; Leskelä HV; Parikka V; Hämäläinen M; Lehenkari P
Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):382-91. PubMed ID: 16364054
[TBL] [Abstract][Full Text] [Related]
6. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
Virtanen SS; Väänänen HK; Härkönen PL; Lakkakorpi PT
Cancer Res; 2002 May; 62(9):2708-14. PubMed ID: 11980672
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of bisphosphonates.
Green JR
Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
[TBL] [Abstract][Full Text] [Related]
8. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells.
Dumon JC; Journé F; Kheddoumi N; Lagneaux L; Body JJ
Eur Urol; 2004 Apr; 45(4):521-8; discussion 528-9. PubMed ID: 15041119
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate treatment inhibits the growth of prostate cancer cells.
Lee MV; Fong EM; Singer FR; Guenette RS
Cancer Res; 2001 Mar; 61(6):2602-8. PubMed ID: 11289137
[TBL] [Abstract][Full Text] [Related]
10. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
11. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.
Corey E; Brown LG; Quinn JE; Poot M; Roudier MP; Higano CS; Vessella RL
Clin Cancer Res; 2003 Jan; 9(1):295-306. PubMed ID: 12538482
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis.
Singh AS; Macpherson GR; Price DK; Schimel D; Figg WD
Oncol Rep; 2006 Mar; 15(3):519-24. PubMed ID: 16465406
[TBL] [Abstract][Full Text] [Related]
14. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
Miwa S; Mizokami A; Keller ET; Taichman R; Zhang J; Namiki M
Cancer Res; 2005 Oct; 65(19):8818-25. PubMed ID: 16204052
[TBL] [Abstract][Full Text] [Related]
15. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
[TBL] [Abstract][Full Text] [Related]
16. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
[TBL] [Abstract][Full Text] [Related]
17. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.
Montague R; Hart CA; George NJ; Ramani VA; Brown MD; Clarke NW
Eur Urol; 2004 Sep; 46(3):389-401; discussion 401-2. PubMed ID: 15306113
[TBL] [Abstract][Full Text] [Related]
18. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid induces autophagic cell death in human prostate cancer cells.
Lin JF; Lin YC; Lin YH; Tsai TF; Chou KY; Chen HE; Hwang TI
J Urol; 2011 Apr; 185(4):1490-6. PubMed ID: 21334668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
